A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

Summary

This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of RVT-1201 in patients with pulmonary arterial hypertension (PAH).

Timeline

Start

2019-08-01

Primary completion

2020-02-24

Completion

2020-02-24

Outcome

Outcome not reported

Stopped (Enrollment): “Inability to enroll”

Drugs

Indications